Current therapy of anemia in patients with chronic kidney disease
Keywords:
anemia, chronic kidney disease, recombinant erythropoietin, hypoxia-inducible factor stabilizers, erythropoietin mimeticsAbstract
Introduction: anemia is a disorder defined by the World Health Organization (WHO) as a hemoglobin (Hb) level <13.0 g/dl for adult men and postmenopausal women; for premenopausal women, Hb <12.0 g/dl is considered. Objective: to describe new therapies, their impact on quality of life, and the relationship between patients diagnosed with anemia secondary to chronic kidney disease. Method: this is a literature review using a PRISMA approach, in which 25 articles were analyzed. Development: the main therapeutic options for CKD anemia were identified, including erythropoiesis-stimulating agents: exogenous EPO (recombinant human erythropoietin (Epoetin) and analogues, EPO-mimetic agents), endogenous EPO-stimulating agents (prolyl-hydroxylase inhibitors (PHI), GATA inhibitors), and agents with other mechanisms of action (anti-hepcidin agents, anti-activin agents). Final considerations: in individuals with chronic kidney disease, the main therapeutic alternatives for treating anemia depend on the severity of the condition and its underlying cause.
Downloads
References
1.PERTUZ, Adolfo, et al. Anemia en enfermedad renal cronica. Archivos de medicina, 2021, vol. 17, no 2, p. 1.
2. Jimenez Romero SA, Loor Vera CL, Mera Macias RC, Castro Jalca JE. Anemia de los Padecimientos Crónicos e Insuficiencia Renal en Adultos: un Impacto en la Salud Mundial. Higía [Internet]. 28 de diciembre de 2022 [citado 8 de abril de 2024];7(2). Disponible en: https://revistas.itsup.edu.ec/index.php/Higia/article/view/740
3. Aleix Cases, Elena González de Antona Sánchez, Giovanna Cadeddu, Maria Mata Lorenzo, Epidemiología y tratamiento de la anemia renal en España: estudio retrospectivo RIKAS,Nefrología,Volume 43, Issue 5, 2023, Pages 562-574, ISSN 0211-6995, https://doi.org/10.1016/j.nefro.2022.04.001
4. Pérez Diez C, Navarro Aznárez H, Lou Arnal LM, Abad Sazatornil MR. Estudio de efectividad y seguridad de los agentes estimulantes de la eritropoyesis en el tratamiento de la anemia asociada a enfermedad renal crónica. Análisis de los factores que influyen en la respuesta. Pharm Care Esp [Internet]. 13 de agosto de 2021 [citado 8 de abril de 2024];23(4):6-18. Disponible en: https://pharmcareesp.com/index.php/PharmaCARE/article/view/639
5. Valencia-Herrera Alex Ramón, Llerena-Cepeda María de Lourdes, Sailema-López Liliana Katherine, Garcell-Duran Katia. Enfoque diagnóstico y terapéutico de la anemia causada por la insuficiencia renal crónica. Rev. inf. cient. [Internet]. 2023 [citado 2024 Abr 05]; 102: e4312. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1028-99332023000100063&lng=es.
6. Braunstein E. Anemia en la enfermedad renal [Internet]. Manual MSD. 2018 [cited 2020 Aug 12]. p. 2. Available from: https://www.msdmanuals.com/es/professional/hematología-y-oncología/anemiascausadas-por-deficiencia-de-la-eritropoyesis/anemia-de-la-enfermedad-renal
7. Heras-Benito M. Anemia renal: tratamientos actuales y moléculas emergentes. Rev Clin Esp [Internet]. 2023;223(7):433–9. Disponible en http://dx.doi.org/10.1016/j.rce.2023.04.005
8. Pérez Diez C, Navarro Aznárez H, Lou Arnal LM, Abad Sazatornil MR. Estudio de efectividad y seguridad de los agentes estimulantes de la eritropoyesis en el tratamiento de la anemia asociada a enfermedad renal crónica. Análisis de los factores que influyen en la respuesta. Pharm Care Esp [Internet]. 13 de agosto de 2021 [citado 6 de abril de 2024];23(4):6-18. Disponible en: https://pharmcareesp.com/index.php/PharmaCARE/article/view/639
9. Masaomi Nangaku, Kazuoki Kondo, Kiichiro Ueta, Yoshimasa Kokado, Genki Kaneko, Hiroki Matsuda, Yutaka Kawaguchi, Yasuhiro Komatsu, Eficacia y seguridad de vadadustat en comparación con darbepoetina alfa en pacientes japoneses anémicos en hemodiálisis: un estudio de fase 3, multicéntrico, aleatorizado, doble estudio ciego, Trasplante de diálisis en nefrología, volumen 36, número 9, septiembre de 2021, páginas 1731–1741, https://doi.org/10.1093/ndt/gfab055
10. GIL RIVERA, Elena, et al. Prevalencia de anemia y tratamiento farmacológico recibido en pacientes con enfermedad renal crónica que acuden al Hospital Escuela Oscar Danilo Rosales Argüello en el primer semestre del año 2021. 2021. Tesis Doctoral.
11. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:2019–32.
12. Portolés J, Quiroga B, López Gómez JM. Nuevos tratamientos estimuladores de eritropoyesis para corregir la anemia de la enfermedad renal. Nefrologia [Internet]. 2016 [citado el 8 de abril de 2024]; 7:6–14. Disponible en: https://revistanefrologia.com/es-relaccionados-nuevos-tratamientos-estimuladores-eritropoyesis-corregir-anemia-enfermedad-renal-articulo-X2013757516595487
13. López-Gómez JM, Abad S, Vega A. Nuevas expectativas en el tratamiento de la anemia en la enfermedad renal crónica. Nefrología [Internet]. 2016;36(3):232–6. Disponible en: http://dx.doi.org/10.1016/j.nefro.2016.03.006
14. Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016, http://dx.doi.org/10.1053/j. ajkd.2015.12.020
15. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009; 361:1848-55.
16. Albiero E, Ruggeri M, Fortuna S, Finotto S, Bernardi M, Madeo D, et al. Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica. 2012; 97:123-
17. Hawinkels LJ, De Vinuesa AG, Paauwe M, Kruithof-de Julio M, Wiercinska E, Pardali E, et al. Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. Clin Cancer Res. 2016; 22:96- 106
18. Johnson RJ, Feehally J, Floege J, Tonelli M. Comprehensive Clinical Nephrology. 6a ed. Filadelfia, PA, Estados Unidos de América: Elsevier - Health Sciences Division; 2024.
19. Susantad T, Fuangthong M, Tharakaraman K, Tit-oon P, Ruchirawat M, Sasisekharan R. Modified recombinant human erythropoietin with potentially reduced immunogenicity. Sci Rep [Internet]. 2021;11(1). Disponible en: http://dx.doi.org/10.1038/s41598-020-80402-1
20. Patel S, Patel JB. Epoetin Alfa. 2024 [citado el 9 de abril de 2024]; Disponible en: https://pubmed.ncbi.nlm.nih.gov/32119434/
21. Robinson DM, Easthope SE. Darbepoetin Alfa: Its use in anemia associated with chronic kidney disease. BioDrugs [Internet]. 2021;19(5):327–43. Disponible en: http://dx.doi.org/10.2165/00063030-200519050-00006
22. Abood SJ, Abdulsahib WK, Al-Radeef MY. The resistance to methoxy polyethylene glycol-epoetin beta in anemic patients of end-stage renal disease. Heliyon [Internet]. 2023;9(2):e13747. Disponible en: http://dx.doi.org/10.1016/j.heliyon.2023.e13747
23. Bartnicki P, Stepien M, Rysz J. Methoxy polyethylene glycol-epoetin beta as a novel erythropoiesis stimulating agent with possible nephroprotective and cardiovascular protective effects in non-dialysis chronic kidney disease patients. Curr Pharm Biotechnol [Internet]. 2017;18(4):303–8. Disponible en: http://dx.doi.org/10.2174/1389201018666170127104801
24. Kessler, M.; Martínez-Castelao, A.; Siamopoulos, KC; Villa, G.; Spinowitz, B.; Dougherty, FC; Beyer, UCERA una vez cada 4 semanas en pacientes con enfermedad renal crónica que no reciben diálisis: el estudio de extensión ARCTOS. Hemodiálisis Int., 2010, 14, 233-239
25. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in chronic kidney disease: From pathophysiology and current treatments, to future agents. Front Med (Lausanne) [Internet]. 2021;8. Disponible en: http://dx.doi.org/10.3389/fmed.2021.642296
26. Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol [Internet]. 2020;31(3):456–68. Disponible en: http://dx.doi.org/10.1681/asn.2019020213
27. Macdougall IC, Bock A, Carrera F, Eckardt K-U, Gaillard C, Van Wyck D, et al. The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant [Internet]. 2014;29(4):843–50. Disponible en: http://dx.doi.org/10.1093/ndt/gft424
28. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int [Internet]. 2015;88(4):905–14. Disponible en: http://dx.doi.org/10.1038/ki.2015.163
29. Bazeley JW, Wish JB. Recent and emerging therapies for iron deficiency in anemia of CKD: A review. Am J Kidney Dis [Internet]. 2022;79(6):868–76. Disponible en: http://dx.doi.org/10.1053/j.ajkd.2021.09.017
30. Zheng Q, Yang H, Sun L, Wei R, Fu X, Wang Y, et al. Efficacy And safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis. Pharmacological Research [Internet]. 2020; 16 (3): 1-13. Disponible en: [DOI:10.1002/14651858.CD010590]
31. Minutolo R, Liberti M, Vittorio S, Sasso F, Borrelli S, De Nicola L, et al. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials.[Internet]. 2024; 7 (5): 1-15. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765094/
Downloads
Published
How to Cite
Issue
Section
ARK
License
Copyright (c) 2025 John Alexander Valencia-Meléndez, Danny Stuart Bohórquez-Rviera, Diego Esteban López-Illescas, Alex Ramón Valencia-Herrera
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Gaceta Médica Estudiantil magazine provides immediate Open Access to its content. It is published under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC) license, which allows sharing (copying and redistributing the material in any medium or format) and adapting (remixing, transforming, and building upon the material), under the terms of acknowledge authorship and not make commercial use of the materials.
